Patents by Inventor Vito J. Palombella

Vito J. Palombella has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20240050437
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Application
    Filed: November 30, 2022
    Publication date: February 15, 2024
    Inventors: Jeffery L. Kutok, David G. Winkler, Vito J. Palombella, Alfredo C. Castro, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Martin R. Tremblay
  • Heterocyclic compounds and uses thereof
    Patent number: 11541059
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: January 3, 2023
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Jeffery L. Kutok, David G. Winkler, Vito J. Palombella, Alfredo C. Castro, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Martin R. Tremblay
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20210000837
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Application
    Filed: March 11, 2020
    Publication date: January 7, 2021
    Inventors: Jeffery L. Kutok, David G. Winkler, Vito J. Palombella, Alfredo C. Castro, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Martin R. Tremblay
  • Heterocyclic compounds and uses thereof
    Patent number: 10675286
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: June 9, 2020
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Jeffery L. Kutok, David G. Winkler, Vito J. Palombella
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20180055852
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Application
    Filed: August 9, 2017
    Publication date: March 1, 2018
    Inventors: Jeffery L. Kutok, David G. Winkler, Vito J. Palombella, Alfredo C. Castro, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Martin R. Tremblay
  • Heterocyclic compounds and uses thereof
    Patent number: 9775844
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: October 3, 2017
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Jeffery L. Kutok, David G. Winkler, Vito J. Palombella, Alfredo C. Castro, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Martin R. Tremblay
  • Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
    Patent number: 9527847
    Abstract: Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating lupus, a fibrotic condition, or inflammatory myopathies and other conditions (e.g., skin conditions).
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: December 27, 2016
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Vito J. Palombella, David G. Winkler
  • TREATMENT OF RHEUMATOID ARTHRITIS AND ASTHMA USING PI3 KINASE INHIBITORS
    Publication number: 20160022692
    Abstract: Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating rheumatoid arthritis or asthma.
    Type: Application
    Filed: October 6, 2015
    Publication date: January 28, 2016
    Inventors: Vito J. PALOMBELLA, Jeffery L. KUTOK
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20150290207
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Application
    Filed: March 18, 2015
    Publication date: October 15, 2015
    Inventors: Jeffery L. KUTOK, David G. WINKLER, Vito J. PALOMBELLA
  • TREATMENT OF LUPUS, FIBROTIC CONDITIONS, AND INFLAMMATORY MYOPATHIES AND OTHER DISORDERS USING PI3 KINASE INHIBITORS
    Publication number: 20140343057
    Abstract: Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating lupus, a fibrotic condition, or inflammatory myopathies and other conditions (e.g., skin conditions).
    Type: Application
    Filed: July 31, 2014
    Publication date: November 20, 2014
    Inventors: Vito J. PALOMBELLA, David G. WINKLER
  • Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
    Patent number: 8828998
    Abstract: Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating lupus, a fibrotic condition, or inflammatory myopathies and other conditions (e.g., skin conditions).
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 9, 2014
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Vito J. Palombella, David G. Winkler
  • TREATMENT OF RHEUMATOID ARTHRITIS AND ASTHMA USING PI3 KINASE INHIBITORS
    Publication number: 20140120060
    Abstract: Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating rheumatoid arthritis or asthma.
    Type: Application
    Filed: March 15, 2013
    Publication date: May 1, 2014
    Applicant: INFINITY PHARMACEUTICALS, INC.
    Inventors: Vito J. Palombella, Jeffrey L. Kutok
  • TREATMENT OF LUPUS, FIBROTIC CONDITIONS, AND INFLAMMATORY MYOPATHIES AND OTHER DISORDERS USING PI3 KINASE INHIBITORS
    Publication number: 20130344061
    Abstract: Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating lupus, a fibrotic condition, or inflammatory myopathies and other conditions (e.g., skin conditions).
    Type: Application
    Filed: March 15, 2013
    Publication date: December 26, 2013
    Applicant: INFINITY PHARMACEUTICALS, INC.
    Inventors: Vito J. PALOMBELLA, David G. WINKLER
  • MEKK1 molecules and uses thereof
    Patent number: 6818427
    Abstract: The invention provides full-length, human isolated nucleic acids molecules, designated MEKK1 nucleic acid molecules, which encode a MEKK family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing MEKK1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a MEKK1 gene has been introduced or disrupted. The invention still further provides isolated MEKK1 proteins, fusion proteins, antigenic peptides and anti-MEKK1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: October 27, 2000
    Date of Patent: November 16, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Vito J. Palombella, Sha-Mei Liao
  • Proteasome regulation of NF-kB activity
    Publication number: 20040097420
    Abstract: Disclosed herein is a method for regulating the activity of NF-&kgr;B in an animal comprising contacting cells of the animal with certain proteasome inhibitors.
    Type: Application
    Filed: January 28, 2003
    Publication date: May 20, 2004
    Applicant: Harvard College
    Inventors: Vito J. Palombella, Alfred L. Goldberg, Thomas P. Maniatis, Oliver Rando
  • Proteasome regulation of NF-KB activity
    Patent number: 6660268
    Abstract: Disclosed herein is a method for regulating the activity of NF-&kgr;B in an animal comprising contacting cells of the animal with certain proteasome inhibitors.
    Type: Grant
    Filed: March 18, 1994
    Date of Patent: December 9, 2003
    Assignee: The President and Fellows of Harvard College
    Inventors: Vito J. Palombella, Alfred L. Goldberg, Thomas P. Maniatis, Oliver Rando
  • Method for monitoring proteasome inhibitor drug action
    Patent number: 6613541
    Abstract: The invention relates to methods for measuring proteasome activity in biological samples. More particularly, then invention relates to methods for monitoring drug action following in vivo administration of a proteasome inhibitor. The invention provides methods and kits for monitoring pharmacodynamic drug action and for determining dose regimen for a proteasome inhibitor. The invention also provides methods for determining baseline proteasome activity in a mammal.
    Type: Grant
    Filed: October 19, 1999
    Date of Patent: September 2, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Gopalakrishna R. Vaddi, Ross L. Stein, Lawrence R. Dick, Vito J. Palombella, Eric S. Lightcap, Peter J. Elliott, Julian Adams, Teresa A. McCormack, Stephen J. Brand, Dan R. Burns